Chosa Oncology Past Earnings Performance
Past criteria checks 0/6
Chosa Oncology's earnings have been declining at an average annual rate of -2245.1%, while the Biotechs industry saw earnings growing at 17.7% annually.
Key information
-2,245.1%
Earnings growth rate
-164.3%
EPS growth rate
| Biotechs Industry Growth | 0.7% |
| Revenue growth rate | n/a |
| Return on equity | -137.5% |
| Net Margin | n/a |
| Next Earnings Update | 10 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Chosa Oncology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -24 | 24 | 0 |
Quality Earnings: CHOSA is currently unprofitable.
Growing Profit Margin: CHOSA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if CHOSA's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare CHOSA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CHOSA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: CHOSA has a negative Return on Equity (-137.52%), as it is currently unprofitable.